NCT03431948: Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer

NCT03431948
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known active central nervous system (CNS) metastases
https://ClinicalTrials.gov/show/NCT03431948

Comments are closed.

Up ↑